Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of MenACYW Conjugate Vaccine in Infants and Toddlers
NCT03632720Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal A, C, Y, W conjugate vaccine in meningococcal infection (3 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA. Started Oct 2018; status: completed.
02
Drugs
meningococcal A, C, Y, W conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT03632720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632720.